Supplementary Figure S1 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

Key Points

• ctDNA tumor fraction changes predict long-term clinical benefit from immune checkpoint inhibitors.
• The study shows significant predictive ability of ctDNA with a focus on real-world settings.
• Research included diverse cancer types across various patients to assess treatment outcomes.
• Findings highlight the importance of ctDNA monitoring for personalized treatment strategies in oncology.

Abstract